“Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study”, J of Skin, vol. 4, no. 1, p. S2, Jan. 2020, Accessed: Apr. 19, 2025. [Online]. Available: https://skin.dermsquared.com/skin/article/view/801